close
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by AKAMPION

< Previous 1 2 3 Next >
Omnix Medical Secures $25 Million in Series C Funding Co-Led by Harel Insurance & Finance and the EIC Fund
From AKAMPION
Via GlobeNewswire
Stanford University Secures NIH Grant to Advance tiakis Biotech´s Elafin (Tiprelestat) Through a U.S. Phase II Trial in Pulmonary Arterial Hypertension
From AKAMPION
Via GlobeNewswire
BellaSeno Establishes High-Profile Clinical Advisory Board
From AKAMPION
Via GlobeNewswire
Mabylon AG Raises CHF 30 Million to Advance Peanut Allergy Lead Program MY006 to Clinical Proof-of-Concept
From AKAMPION
Via GlobeNewswire
MetrioPharm’s MP1032 Receives EMA Orphan Drug Designation in Duchenne Muscular Dystrophy
From AKAMPION
Via GlobeNewswire
Ebenbuild Secures Euro 2.3 Million EIC Grant to Scale Digital Twin Platform for Respiratory Health
From AKAMPION
Via GlobeNewswire
Thermosome Reports Encouraging Clinical Data of THE001 in Advanced Soft Tissue Sarcomas
From AKAMPION
Via GlobeNewswire
Captain T Cell Joins Bayer Co.Lab Berlin to Accelerate Autologous and Allogeneic TCR-T Cell Therapy Programs for Cancer Patients
From AKAMPION
Via GlobeNewswire
tiakis Biotech AG Announces Appointment of ex-Actelion Executive Christoph Schmidt as New Supervisory Board Member
From AKAMPION
Via GlobeNewswire
Thermosome Receives U.S. Orphan Drug Designation for Lead Compound THE001, Expands Patent Estate
From AKAMPION
Via GlobeNewswire
Dr. Stephan Rietiker elected as new Chairman of the Board of MetrioPharm AG
From AKAMPION
Via GlobeNewswire
1STBIO and LigaChemBio Announce Strategic R&D and Licensing Option Agreement
From AKAMPION
Via GlobeNewswire
Four new members elected to the Board of Directors of MetrioPharm AG
From AKAMPION
Via GlobeNewswire
1ST Biotherapeutics Joins The Michael J. Fox Foundation’s LITE Program to Advance LRRK2-Based Parkinson’s Disease Research
From AKAMPION
Via GlobeNewswire
Ebenbuild Contributes Cutting-Edge Digital Lung Simulations to Pulmonary Fibrosis Drug Development
From AKAMPION
Via GlobeNewswire
New Clinical Data on BellaSeno’s Novel, Resorbable Breast Implants Presented at The Aesthetic MEET 2025
From AKAMPION
Via GlobeNewswire
AMYRA Publishes Landmark Review Supporting New Gluten Digestion Approach for Celiac Disease
From AKAMPION
Via GlobeNewswire
BellaSeno Successfully Completes Two Clinical Trials with Novel, Resorbable Breast Implants
From AKAMPION
Via GlobeNewswire
tiakis Biotech AG Receives Positive Scientific Advice from the U.S. FDA for Planned Phase II Trial of Tiprelestat
From AKAMPION
Via GlobeNewswire
Next-generation RNA company Inverna Therapeutics launched by Argobio and University of Southern Denmark
From AKAMPION
Via GlobeNewswire
tiakis Biotech AG Reports Clinical Phase Ib/II Trial Results of Tiprelestat for the Treatment of Hospitalized COVID-19 Patients
From AKAMPION
Via GlobeNewswire
Thermosome Initiates Final Dose Level in Phase I Trial of Lead Compound THE001
From AKAMPION
Via GlobeNewswire
Thermosome Presents Encouraging Initial Clinical Data from Phase I Trial of Lead Compound THE001
From AKAMPION
Via GlobeNewswire
Ebenbuild Appoints Charles A. Taylor, PhD as Chairman of the Board
From AKAMPION
Via GlobeNewswire
AMYRA Successfully Demonstrates a New Therapeutic Paradigm for Gluten-Related Disorders in a First-in-Human Study
From AKAMPION
Via GlobeNewswire
Preliminary Data of BellaSeno’s Clinical Trial on Scaffold-Guided Breast Regeneration Presented at the 93rd Annual Plastic Surgery Meeting in San Diego, CA
From AKAMPION
Via GlobeNewswire
Mabylon AG Receives Research Grants Totaling More Than CHF 1.3 Million for Amyotrophic Lateral Sclerosis (ALS) and Inflammasome Programs
From AKAMPION
Via GlobeNewswire
ImmunOs Therapeutics AG Raises $11 Million and Further Strengthens Investor Base
From AKAMPION
Via GlobeNewswire
ImmunOs Therapeutics Expands Phase I Clinical Trial of IOS-1002 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Solid Tumors
From AKAMPION
Via GlobeNewswire
BellaSeno Reports Positive Interim Findings of Australian Clinical Trials in Breast Scaffold Patients
From AKAMPION
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Starting at $3.75/week.

Subscribe Today